In accordance with several studies that showed that exendin-4 causes a significant reduction in ALT levels in diabetic patients with NAFLD [21,37], we found that ExA treatment for 6 weeks contributed to significant reductions in serum ALT and AST levels in HFD/STZ mice. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.